




AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No. PC31283(3376)	
Applicant(s): Fedde et al						
Application No. 09/941,206	Filing Date 08/28/2001	Examiner J. Kim	Customer No. 26648	Group Art Unit 1617	Confirmation No. 5686	
Invention: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION						
COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	4 -	20 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	1 -	3 =	0	x \$200.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<div style="display: flex; flex-direction: row;"><div style="flex: 1;"><p><input checked="" type="checkbox"/> No additional fee is required for amendment.</p><p><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____</p><p><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</p><p><input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025</p><p><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</p><p><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</p><p><input type="checkbox"/> Payment by credit card. Form PTO-2038.</p></div><div style="flex: 1; padding-left: 20px;"><p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p></div></div>						
 _____ <i>Signature</i>			Dated: 08/18/2005			
Christopher W. Slavinsky Reg. No. 54,456			<div style="font-size: small;">I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</div> <div style="text-align: center;">08/18/2005 (Date)</div> <div style="text-align: center;"> _____ <i>Signature of Person Mailing Correspondence</i></div> <div style="text-align: center;">Michelle R. Becker _____ <i>Typed or Printed Name of Person Mailing Correspondence</i></div>			
cc:						

Serial No. 09/941,206

3376/1/US (26648)

Amendment B



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Fedde et al.
Serial No.: 09/941,206
Filed: 28 Aug 2001
Title: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE
COGNITIVE FUNCTION
Group Art Unit: 1617
Examiner: Jennifer M. Kim
Confirmation No.: 5686
Docket No.: PC31283 (3376/1/US)

CERTIFICATE OF MAILING

I certify that this paper, together with any attachments thereto, being deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL (EV580754377US) in an envelope addressed to: Mail Stop RCE, Commissioner for patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 18, 2005.


Michelle R. Becker

August 18, 2005

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

AMENDMENT B

This paper is responsive to the Final Office Action mailed May 19, 2005 in the above referenced application. Applicants respectfully request entry of the proposed amendments and request reconsideration of the claims as amended.

Amendments IN THE CLAIMS are reflected in the listing of claims, which begins on page 2 of this paper.

REMARKS on the present amendment and in response to the Final Office Action dated May 19, 2005 begin on page 6 of this paper.